S&P 500   0.52 (-8.53%)
DOW   0.52 (-8.53%)
QQQ   270.38 (+0.37%)
AAPL   438.66 (+0.67%)
MSFT   213.29 (-1.50%)
FB   249.83 (-0.85%)
GOOGL   1,473.30 (-0.64%)
AMZN   3,138.83 (+0.87%)
NVDA   449.11 (+1.98%)
CGC   19.32 (+1.36%)
BABA   262.20 (+1.65%)
TSLA   1,487.00 (+0.13%)
MU   51.30 (+1.81%)
GE   6.14 (+0.49%)
AMD   85.04 (+9.49%)
T   30.01 (+1.32%)
F   6.86 (+2.54%)
ACB   10.73 (+2.98%)
GILD   70.88 (-1.18%)
NFLX   509.64 (+2.21%)
DIS   117.29 (+0.81%)
BAC   25.01 (+0.08%)
BA   165.07 (+1.73%)
S&P 500   0.52 (-8.53%)
DOW   0.52 (-8.53%)
QQQ   270.38 (+0.37%)
AAPL   438.66 (+0.67%)
MSFT   213.29 (-1.50%)
FB   249.83 (-0.85%)
GOOGL   1,473.30 (-0.64%)
AMZN   3,138.83 (+0.87%)
NVDA   449.11 (+1.98%)
CGC   19.32 (+1.36%)
BABA   262.20 (+1.65%)
TSLA   1,487.00 (+0.13%)
MU   51.30 (+1.81%)
GE   6.14 (+0.49%)
AMD   85.04 (+9.49%)
T   30.01 (+1.32%)
F   6.86 (+2.54%)
ACB   10.73 (+2.98%)
GILD   70.88 (-1.18%)
NFLX   509.64 (+2.21%)
DIS   117.29 (+0.81%)
BAC   25.01 (+0.08%)
BA   165.07 (+1.73%)
S&P 500   0.52 (-8.53%)
DOW   0.52 (-8.53%)
QQQ   270.38 (+0.37%)
AAPL   438.66 (+0.67%)
MSFT   213.29 (-1.50%)
FB   249.83 (-0.85%)
GOOGL   1,473.30 (-0.64%)
AMZN   3,138.83 (+0.87%)
NVDA   449.11 (+1.98%)
CGC   19.32 (+1.36%)
BABA   262.20 (+1.65%)
TSLA   1,487.00 (+0.13%)
MU   51.30 (+1.81%)
GE   6.14 (+0.49%)
AMD   85.04 (+9.49%)
T   30.01 (+1.32%)
F   6.86 (+2.54%)
ACB   10.73 (+2.98%)
GILD   70.88 (-1.18%)
NFLX   509.64 (+2.21%)
DIS   117.29 (+0.81%)
BAC   25.01 (+0.08%)
BA   165.07 (+1.73%)
S&P 500   0.52 (-8.53%)
DOW   0.52 (-8.53%)
QQQ   270.38 (+0.37%)
AAPL   438.66 (+0.67%)
MSFT   213.29 (-1.50%)
FB   249.83 (-0.85%)
GOOGL   1,473.30 (-0.64%)
AMZN   3,138.83 (+0.87%)
NVDA   449.11 (+1.98%)
CGC   19.32 (+1.36%)
BABA   262.20 (+1.65%)
TSLA   1,487.00 (+0.13%)
MU   51.30 (+1.81%)
GE   6.14 (+0.49%)
AMD   85.04 (+9.49%)
T   30.01 (+1.32%)
F   6.86 (+2.54%)
ACB   10.73 (+2.98%)
GILD   70.88 (-1.18%)
NFLX   509.64 (+2.21%)
DIS   117.29 (+0.81%)
BAC   25.01 (+0.08%)
BA   165.07 (+1.73%)
Log in

NASDAQ:ASLNASLAN PHARMACEU/ADR Stock Price, Forecast & News

$1.63
+0.04 (+2.52 %)
(As of 08/4/2020 04:00 PM ET)
Add
Compare
Today's Range
$1.53
Now: $1.63
$1.68
50-Day Range
$1.51
MA: $1.87
$2.19
52-Week Range
$0.35
Now: $1.63
$8.18
Volume65,979 shs
Average Volume199,574 shs
Market Capitalization$52.24 million
P/E RatioN/A
Dividend YieldN/A
Beta3.09
ASLAN Pharmaceuticals Limited, a clinical-stage oncology-focused biopharmaceutical company, engages in the development of drugs for prevalent cancers. It targets diseases that are prevalent in Asia, and orphan indications in the United States and Europe. The company's lead program, varlitinib, is a reversible small molecule pan-human epidermal growth factor receptor, or pan-HER, inhibitor that targets the human epidermal growth factor receptors HER1, HER2, and HER4. Its Varlitinib is currently being studied in a global pivotal clinical trial for biliary tract cancer. It is also conducting a Phase II/III clinical trial of varlitinib for gastric cancer; and testing in a single-arm pivotal clinical trial in biliary tract cancer in China. In addition, the company is developing ASLAN003, an orally active potent inhibitor of human dihydroorotate dehydrogenase that is in Phase II clinical trials to treat acute myeloid leukemia; and ASLAN004, an interleukin 4/interleukin 13 receptor antibody for the treatment of severe atopic dermatitis and asthma. It has rights to develop, manufacture, and commercialize varlitnib for all human and animal therapeutic, diagnostic, and prophylactic uses. ASLAN Pharmaceuticals Limited has partnerships with Array BioPharma, Bristol-Myers Squibb, Almirall, and CSL Limited. ASLAN Pharmaceuticals Limited was founded in 2010 and is headquartered in Singapore.
Read More
ASLAN PHARMACEU/ADR logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.13 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ASLN
CUSIPN/A
CIKN/A
Phone65-6222-4235

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3 million
Book Value($0.02) per share

Profitability

Net Income$-47,020,000.00
Return on Equity-10,427.34%

Miscellaneous

EmployeesN/A
Market Cap$52.24 million
Next Earnings Date10/29/2020 (Estimated)
OptionableNot Optionable
$1.63
+0.04 (+2.52 %)
(As of 08/4/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ASLN News and Ratings via Email

Sign-up to receive the latest news and ratings for ASLN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











ASLAN PHARMACEU/ADR (NASDAQ:ASLN) Frequently Asked Questions

How has ASLAN PHARMACEU/ADR's stock been impacted by COVID-19 (Coronavirus)?

ASLAN PHARMACEU/ADR's stock was trading at $1.59 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ASLN stock has increased by 2.5% and is now trading at $1.63.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of ASLAN PHARMACEU/ADR?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ASLAN PHARMACEU/ADR in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for ASLAN PHARMACEU/ADR
.

When is ASLAN PHARMACEU/ADR's next earnings date?

ASLAN PHARMACEU/ADR is scheduled to release its next quarterly earnings announcement on Thursday, October 29th 2020.
View our earnings forecast for ASLAN PHARMACEU/ADR
.

How were ASLAN PHARMACEU/ADR's earnings last quarter?

ASLAN PHARMACEU/ADR (NASDAQ:ASLN) issued its quarterly earnings data on Monday, July, 13th. The company reported ($0.10) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.09) by $0.01.
View ASLAN PHARMACEU/ADR's earnings history
.

What price target have analysts set for ASLN?

3 brokerages have issued 12-month price targets for ASLAN PHARMACEU/ADR's stock. Their forecasts range from $5.00 to $8.00. On average, they expect ASLAN PHARMACEU/ADR's stock price to reach $6.33 in the next year. This suggests a possible upside of 288.5% from the stock's current price.
View analysts' price targets for ASLAN PHARMACEU/ADR
.

Has ASLAN PHARMACEU/ADR been receiving favorable news coverage?

News headlines about ASLN stock have trended somewhat positive this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. ASLAN PHARMACEU/ADR earned a coverage optimism score of 0.8 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next few days.
View the latest news about ASLAN PHARMACEU/ADR
.

Who are some of ASLAN PHARMACEU/ADR's key competitors?

What other stocks do shareholders of ASLAN PHARMACEU/ADR own?

Who are ASLAN PHARMACEU/ADR's key executives?

ASLAN PHARMACEU/ADR's management team includes the following people:
  • Dr. Carl Alan Jason Morton Firth, Chairman & CEO (Age 46)
  • Mr. Kiran Asarpota, VP of Fin. (Age 40)
  • Charlie Hsu, Investor Relations Director
  • Mr. Ben Goodger, Gen. Counsel (Age 56)
  • Chi-Chin Wang, IR & Corp. Devel. Director

When did ASLAN PHARMACEU/ADR IPO?

(ASLN) raised $60 million in an IPO on Friday, May 4th 2018. The company issued 7,500,000 shares at a price of $8.05 per share. Leerink Partners and Piper Jaffray served as the underwriters for the IPO and BTIG, H.C. Wainwright and CLSA were co-managers.

What is ASLAN PHARMACEU/ADR's stock symbol?

ASLAN PHARMACEU/ADR trades on the NASDAQ under the ticker symbol "ASLN."

How do I buy shares of ASLAN PHARMACEU/ADR?

Shares of ASLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ASLAN PHARMACEU/ADR's stock price today?

One share of ASLN stock can currently be purchased for approximately $1.63.

How big of a company is ASLAN PHARMACEU/ADR?

ASLAN PHARMACEU/ADR has a market capitalization of $52.24 million and generates $3 million in revenue each year. The company earns $-47,020,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis.

What is ASLAN PHARMACEU/ADR's official website?

The official website for ASLAN PHARMACEU/ADR is www.aslanpharma.com.

How can I contact ASLAN PHARMACEU/ADR?

ASLAN PHARMACEU/ADR's mailing address is 83 CLEMENCEAU AVENUE 12-03 UE SQUARE, SINGAPORE U0, 239920. The company can be reached via phone at 65-6222-4235 or via email at [email protected]

This page was last updated on 8/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.